Regimen

No. of patients (%), n = 18

FOLFIRI + bevacizumab

5 (27.7)

IRIS + bevacizumab

4 (22.2)

CAPIRI + bevacizumab

4 (22.2)

CPT-11 + cetuximab

4 (22.2)

FOLFIRI + panitumumab

1 (5.55)